Trial intelligence / Profile preview

Weekly docetaxel as neoadjuvant and concomitant therapy in high-risk locally advanced prostate cancer

2008-003525-16Phase 2Terminated

Sponsor: Istituti Fisioterapici Ospitalieri
Start: Jun 2008
Modality: Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of docetaxel in prostate cancer (PCa), sponsored by Istituti Fisioterapici Ospitalieri. Primary endpoint: Early and late toxicity. Started Jun 2008; status: terminated.

Drugs

docetaxel

Conditions

prostate cancer (PCa)

Beyond the preview

Go deeper on 2008-003525-16.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2008-003525-16.